The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50 ...
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for ...
The decision comes just over a year after the FDA approved Arexvy for use in adults aged 60 years and older GSK’s Arexvy has become the first respiratory syncytial virus (RSV) vaccine to be ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virusvaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...